Docoh
Loading...

ICCC Immucell

ImmuCell Corporation's purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain™, a novel treatment for subclinical mastitis without a milk discard requirement that provides an alternative to traditional antibiotics.

Company profile

Ticker
ICCC
Exchange
CEO
Michael Brigham
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
10382980

ICCC stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

13 May 21
2 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Immucell earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 6.81M 6.81M 6.81M 6.81M 6.81M 6.81M
Cash burn (monthly) 47.76K 91.56K 147.1K 180.36K 207.85K 13.79K
Cash used (since last report) 195.78K 375.29K 602.97K 739.31K 851.97K 56.51K
Cash remaining 6.61M 6.43M 6.2M 6.07M 5.95M 6.75M
Runway (months of cash) 138.4 70.2 42.2 33.6 28.6 489.7

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
17 Jun 21 Paul R Wainman Incentive Stock Options Common Stock Grant Aquire A No No 10.04 10,000 100.4K 10,000
17 Jun 21 David Scott Tomsche Incentive Stock Options Common Stock Grant Aquire A No No 10.04 10,000 100.4K 10,000
17 Jun 21 David Cunningham Incentive Stock Options Common Stock Grant Aquire A No No 10.04 10,000 100.4K 10,000
17 Jun 21 Steven T. Rosgen Incentive Stock Options Common Stock Grant Aquire A No No 10.04 10,000 100.4K 10,000
17 Jun 21 Gloria F Basse Incentive Stock Options Common Stock Grant Aquire A No No 10.04 10,000 100.4K 10,000
29 Jun 20 Gloria F Basse Incentive Stock Options Common Stock Grant Aquire A No No 4.81 15,000 72.15K 15,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

9.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 27 25 +8.0%
Opened positions 4 2 +100.0%
Closed positions 2 4 -50.0%
Increased positions 8 5 +60.0%
Reduced positions 7 4 +75.0%
13F shares
Current Prev Q Change
Total value 7.2M 4.31M +66.9%
Total shares 746.72K 724K +3.1%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Renaissance Technologies 187.58K $1.81M +11.6%
Vanguard 134.61K $1.3M +44.2%
Overbrook Management 87.43K $843K -0.7%
MS Morgan Stanley 55.07K $531K -4.3%
Perritt Capital Management 55K $530K 0.0%
Strategic Financial Services, Inc, 30.03K $289K 0.0%
Geode Capital Management 20.43K $196K 0.0%
Wedge Capital Management L L P 20.38K $197K NEW
BLK Blackrock 19.32K $187K +10.5%
Shufro Rose & Co 17.91K $173K -64.7%
Largest transactions
Shares Bought/sold Change
Vanguard 134.61K +41.23K +44.2%
Shufro Rose & Co 17.91K -32.76K -64.7%
Wedge Capital Management L L P 20.38K +20.38K NEW
Renaissance Technologies 187.58K +19.43K +11.6%
HM Payson & Co 2K -18.5K -90.2%
Dimensional Fund Advisors 15.1K +15.1K NEW
RBF Capital 0 -13.09K EXIT
Ingalls & Snyder 0 -10K EXIT
O'shaughnessy Asset Management 2.84K +2.84K NEW
Minerva Advisors 11.96K -2.6K -17.9%

Financial report summary

?
Competition
PfizerZoetis
Management Discussion
  • Total product sales during the three-month period ended March 31, 2021 decreased by 16%, or $803,000, to $4.1 million from $4.9 million during the three-month period ended March 31, 2020, with domestic sales decreasing by 18% and international sales decreasing by 5% in comparison to the three-month period ended March 31, 2020. International sales aggregated 13% and 11% of total sales during the three-month periods ended March 31, 2021 and 2020, respectively. The compound annual growth rate of our total product sales during the ten years ended December 31, 2020 was approximately 13%. The compound annual growth rate of our total product sales during the three years ended December 31, 2020 was approximately 18%. Sales achieved during the first quarter of 2021 were the annualized equivalent of almost 100% of the $16.5 million that we estimate to be our current annual production capacity. As of December 31, 2020, we had depleted our available finished goods inventory and had a backlog of orders worth approximately $1.8 million, compared to backlogs of approximately $1.4 million and $0 as of March 31, 2020 and December 31, 2019, respectively. The backlog increased to approximately $3.1 million as of March 31, 2021 (see further discussion about the valuation of the backlog, and our plan to eliminate it, below). While this is a very positive indication about the strong demand for our First Defense® product line, not being able to meet the needs of our customers presently could result in the loss of some customers that seek alternative scours management products during this period of short supply and may not resume purchasing our product when we have eliminated the backlog. We missed some business during the peak season of 2021. As our product mix shifts in favor of Tri-Shield First Defense®, it has become more difficult to achieve our estimated production capacity. After our increased production capacity comes on-line at the end of the second quarter of 2021, and assuming we produce and sell to plan, we expect sales for the year ending December 31, 2021 to be greater than sales recorded during the year ended December 31, 2020. A precise estimation of the amount of the recovery from the first quarter sales drop to the anticipated year-over-year sales increase is very difficult to make at this point, given the uncertainties related to the impacts of new business opportunities missed due to COVID-related restrictions and customers lost (that may or may not return at or above prior levels of purchasing) and other factors experienced during the period of order backlog.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Good
New words: analytical, behavior, belief, buildup, clear, concept, contractor, contributor, COVID, culture, deeper, depleted, DVM, easily, environment, equivalent, GSB, guideline, introducing, knock, lack, methodology, missed, mode, official, online, Overview, preliminary, prepay, prioritize, regained, relieved, relocation, resume, retrospective, shift, shutdown, superseded, swing, transition, unmet, upfront, upgrade, urgent, vacating, vehicle, waive, waiver, warehousing
Removed: Amherst, antibiotic, antibody, assumption, audited, basic, bioterrorism, China, closely, collateral, combating, comply, content, cure, diagnostic, diarrhea, diluted, draft, drinking, economically, eligibility, export, flat, flow, hedging, hypothetical, imputed, incrementally, instrument, Isolate, Kingdom, legacy, link, lived, nutritional, opposed, partial, passive, pipeline, polyclonal, producer, released, repayment, repurchased, resistance, resolved, slightly, split, statistically, steady, strategic, structure, study, TDBank, terrorism, threat, tool, transparency, turn, University, unrestricted, utility, water, weaken, wide, widespread, worked, world, wrote